Artificial Intelligence
Filter News
Found 18 articles
-
Eli Lilly has signed a multi-year contract with animal genomics biotech Fauna Bio to use its artificial intelligence platform to discover drug targets for obesity in a deal worth nearly half a billion dollars.
-
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny
12/13/2023
This week, we discuss the two major FDA approvals for sickle cell from Vertex/CRISPR and bluebird bio; Axcella and the future of long-covid treatments, Vanda's $100m purchase and AI regulatory developments in Europe. -
Fast and furious evolution: how to ensure AI is catalyst for positive societal change with Micros...
12/12/2023
In this episode we dive into regulation, real-time management, and AI's various applications and how it can streamline different processes with guests from Microsoft and IQVIA. -
In this episode, hear from senior leaders at Microsoft and IQVIA to get their take on how generative AI is impacting productivity, employee engagement and how to mitigate risks.
-
In this third episode of Denatured's series on AI in drug discovery, we discuss patient behavior and its influence on clinical trials and AI models with guests from GSK, IQVIA, Exelixis and DataHow.
-
ALTO-300 was significantly more effective in major depressive disorder patients with a specific EEG biomarker than in those without, according to results from an Alto Neuroscience Phase IIa study.
-
Johnson & Johnson’s AI investments include a research facility in San Francisco and a data science workforce of approximately 6,000 employees.
-
Listen to this in-depth discussion on how AI can help identify end-to-end data weaknesses, as well as broader implications regarding the inevitability of human interaction, with guests from GSK, IQVIA, Exelixis and DataHow.
-
White House and Congress Propose AI Legislation as FDA Continues to Act as AI Regulatory Gatekeeper
11/22/2023
Both the White House and Congress have proposed legislation for the appropriate use of AI while the FDA continues to serve as the gatekeeper for patient privacy and safety. -
This is part one of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Topics explored are ROI, human bias, data challenges, data management plans, and human expertise.
-
In this deep dive, BioSpace examines how small, medium and large companies are using artificial intelligence and machine learning to enhance their drug discovery efforts.
-
More and more companies are turning to artificial intelligence for drug safety prediction, but as with any new application of AI, experts urge caution.
-
The biopharma industry is moving toward using AI to try to determine how well a given person would perform in a role, with applications that go beyond recruiting.
-
High multiplexed patient-centric assays could reduce patient burden
-
A Discussion with IQVIA’s Michelle Gyzen Sr. Director, Regulatory Affairs and Drug Development Solutions
-
New platforms are emerging to help biopharma companies fill their human studies more efficiently, but barriers remain to their successful implementation.
-
AI and machine learning could transform drug discovery, but first, practitioners must overcome ethical challenges en route to medicines for all.
-
Google and Microsoft are already making inroads into drug development, but smaller biotechs focused on AI may end up leading the charge.